Chief Commercial Officer Colleen Sjogren purchases 50,000 shares of NUVB at $1.81; cluster of 4 other insiders buying within 14 days.
Sjogren purchased 50,000 shares at $1.81 on 2025-06-16, raising her holdings from 31,000 to 81,000 shares (+161.3% vs pre-transaction holdings). This buy occurs alongside a cluster pattern: 4 other insiders also purchased within the past 14 days, suggesting coordinated or aligned perspectives on valuation across leadership. The timing context is notable—the stock trades at $1.79 current price, down 22.2% over 30 days and down 53.3% from its 52-week high of $3.83. Nuvation Bio posted $3.1M revenue in its latest quarter against $-53.2M net income, indicating the company remains unprofitable and burning significant cash. The convergence of insider accumulation during a steep drawdown coincides with fundamental distress, warranting closer examination of management's investment thesis and the company's path to profitability.